Huntington National Bank boosted its stake in Gilead Sciences (NASDAQ:GILD) by 0.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 212,345 shares of the biopharmaceutical company’s stock after buying an additional 1,578 shares during the quarter. Huntington National Bank’s holdings in Gilead Sciences were worth $15,212,000 at the end of the most recent quarter.
Other hedge funds also recently made changes to their positions in the company. Capital International Investors raised its position in shares of Gilead Sciences by 86.6% during the third quarter. Capital International Investors now owns 11,217,015 shares of the biopharmaceutical company’s stock worth $908,803,000 after acquiring an additional 5,205,983 shares during the last quarter. Sanders Capital LLC increased its holdings in Gilead Sciences by 102.9% in the fourth quarter. Sanders Capital LLC now owns 9,910,493 shares of the biopharmaceutical company’s stock valued at $757,119,000 after purchasing an additional 5,026,015 shares during the last quarter. Skandinaviska Enskilda Banken AB publ increased its holdings in Gilead Sciences by 230.0% in the third quarter. Skandinaviska Enskilda Banken AB publ now owns 4,927,585 shares of the biopharmaceutical company’s stock valued at $399,233,000 after purchasing an additional 3,434,450 shares during the last quarter. CI Global Investments Inc. grew its stake in Gilead Sciences by 5,461.1% in the fourth quarter. CI Global Investments Inc. now owns 3,317,627 shares of the biopharmaceutical company’s stock valued at $237,675,000 after acquiring an additional 3,257,969 shares during the period. Finally, Renaissance Technologies LLC grew its stake in Gilead Sciences by 35.0% in the second quarter. Renaissance Technologies LLC now owns 10,407,848 shares of the biopharmaceutical company’s stock valued at $736,667,000 after acquiring an additional 2,700,600 shares during the period. 77.91% of the stock is currently owned by institutional investors and hedge funds.
A number of research analysts have issued reports on the company. Barclays reissued an “overweight” rating and issued a $95.00 target price (up from $90.00) on shares of Gilead Sciences in a research note on Tuesday, March 6th. BidaskClub cut Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, March 3rd. Zacks Investment Research raised Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Wednesday, February 28th. Royal Bank of Canada reissued a “buy” rating and set a $94.00 price target on shares of Gilead Sciences in a research report on Friday, February 23rd. Finally, Leerink Swann reissued a “market perform” rating and set a $80.00 price target (down from $83.00) on shares of Gilead Sciences in a research report on Thursday, February 22nd. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Gilead Sciences presently has an average rating of “Buy” and an average target price of $88.61.
NASDAQ:GILD traded down $1.41 during trading hours on Friday, hitting $73.41. 6,439,529 shares of the company were exchanged, compared to its average volume of 6,802,121. Gilead Sciences has a one year low of $63.76 and a one year high of $89.54. The company has a quick ratio of 2.67, a current ratio of 2.74 and a debt-to-equity ratio of 1.53. The firm has a market cap of $95,715.63, a P/E ratio of 8.58, a P/E/G ratio of -1.69 and a beta of 1.19.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.67 by $0.11. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The firm had revenue of $5.95 billion during the quarter, compared to analyst estimates of $5.71 billion. During the same period last year, the company posted $2.70 EPS. The business’s quarterly revenue was down 18.7% on a year-over-year basis. equities research analysts expect that Gilead Sciences will post 6.21 EPS for the current year.
The company also recently announced a quarterly dividend, which was paid on Thursday, March 29th. Investors of record on Friday, March 16th were given a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a yield of 3.11%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend was Thursday, March 15th. Gilead Sciences’s payout ratio is presently 26.64%.
In related news, EVP Gregg H. Alton sold 30,000 shares of the business’s stock in a transaction dated Thursday, January 11th. The stock was sold at an average price of $79.00, for a total value of $2,370,000.00. Following the completion of the sale, the executive vice president now directly owns 57,114 shares of the company’s stock, valued at approximately $4,512,006. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $83.56, for a total value of $4,178,000.00. Following the transaction, the chairman now owns 3,046,766 shares of the company’s stock, valued at approximately $254,587,766.96. The disclosure for this sale can be found here. Insiders sold a total of 426,934 shares of company stock valued at $33,847,101 over the last ninety days. 1.30% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: “Huntington National Bank Has $15.21 Million Holdings in Gilead Sciences (GILD)” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/04/08/gilead-sciences-inc-gild-position-raised-by-huntington-national-bank.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.